Cargando…

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors

BACKGROUND: Immunotherapy against solid tumors has long been hampered by the development of immunosuppressive tumor microenvironment, and the lack of a specific tumor-associated antigen that could be targeted in different kinds of solid tumors. Human leukocyte antigen G (HLA-G) is an immune checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jan, Chia-Ing, Huang, Shi-Wei, Canoll, Peter, Bruce, Jeffrey N, Lin, Yu-Chuan, Pan, Chih-Ming, Lu, Hsin-Man, Chiu, Shao-Chih, Cho, Der-Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524382/ https://www.ncbi.nlm.nih.gov/pubmed/34663641 http://dx.doi.org/10.1136/jitc-2021-003050

Ejemplares similares

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
por: Lontos, Konstantinos, et al.
Publicado: (2023)

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
por: Foster, Jessica B, et al.
Publicado: (2022)

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
por: Mancikova, Veronika, et al.
Publicado: (2020)

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
por: Johnson, P Connor, et al.
Publicado: (2022)

CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype
por: Lee, Sang Yun, et al.
Publicado: (2023)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia
por: Trad, Rim, et al.
Publicado: (2022)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
por: Qin, Haiying, et al.
Publicado: (2021)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022)

Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
por: Li, Qingyang, et al.
Publicado: (2022)

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
por: Makkouk, Amani, et al.
Publicado: (2021)

Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens
por: Bernhardt, Anna Luise, et al.
Publicado: (2021)

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021)

Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors
por: Rettman, Pauline, et al.
Publicado: (2021)

'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
por: Sinha, Debottam, et al.
Publicado: (2021)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
por: Tvingsholm, Siri Amanda, et al.
Publicado: (2023)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy
por: Choi, Seung Hee, et al.
Publicado: (2022)

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
por: Toyoda, Takahide, et al.
Publicado: (2020)

Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants
por: Conde, Enrique, et al.
Publicado: (2021)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy
por: Davari, Kathrin, et al.
Publicado: (2021)

Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis
por: Li, Celine Man Ying, et al.
Publicado: (2023)

Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens
por: Bekri, Selma, et al.
Publicado: (2022)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2(+) T cells activities after hematopoietic transplantation for blood malignancies
por: Liu, Jiangying, et al.
Publicado: (2020)

Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
por: Liu, Dan, et al.
Publicado: (2021)

Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
por: Brownlie, Demi, et al.
Publicado: (2021)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
por: Kumar, Anil, et al.
Publicado: (2023)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
por: Abdin, Shifaa M., et al.
Publicado: (2021)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7vhp7sjsl7stdshfbjbpfnibip